An added bonus of transferring the ward in a single day and as an entity was the strengthening of the relationship between the patients and the staff, as all worked together to deal with the task in hand. The move to the new ward also had the impressive effect of achieving, over time, the complete cessation of smoking within the ward among both staff and patients.
Our observations during the 2 years following the move indicate that there has indeed been a change in the patients. The nature of their illnesses has not changed, nor has the length of hospitalization; however, there have been real gains in their sense of satisfaction and quality of life.
Yuval Melamed, MD Avner Elizur, MD Bat Yam, Israel
Sildenafil Citrate for Female Orgasmic Disorder
Dear Editor:
Female orgasmic disorder is common and there appear to be many etiologic factors associated with its development (1) . Comer has reported that 20% to 30% of women have never reached, or rarely reach, orgasm during intercourse (2) . There are several case reports and 1 small study discussing the role of sildenafil citrate for the treatment of anorgasmia induced in women by selective serotonin reuptake inhibitors (SSRIs) (3) (4) (5) (6) . However, we found no published data regarding the use of sildenafil to treat the disorder in cases unrelated to SSRI therapy. We report such a case of acquired female orgasmic disorder successfully treated with sildenafil.
Case Report
Ms B is a 42-year-old woman who was anorgasmic for 15 years. Her anorgasmia commenced after the birth of her last child, but she continued to have a robust libido. Ms B had no history of sexual dysfunction prior to this time. Eight years after she became anorgasmic, Ms B was diagnosed with major depressive disorder (MDD). This was initially treated with paroxetine, with good clinical effect. Five years later, the antidepressant was changed to venlafaxine because of worsening mood. After several years of stable mood, Ms B reported dissatisfaction with her ongoing anorgasmia. The venlafaxine was gradually reduced from 300 mg to 75 mg daily, with no change in either mood or ability to reach orgasm, despite vigorous sexual activity. Subsequently, Ms B was prescribed 25 mg sildenafil and instructed to take the medication orally about 1 hour before expected sexual activity. The treatment was unsuccessful in correcting her anorgasmia. The sildenafil was increased to 50 mg, with the result that Ms B regained her ability to reach orgasm. She reported no side effects from the sildenafil. Discontinuation of sildenafil resulted in anorgasmia.
This case is not a controlled study, and it is possible that the response was due to placebo. However, Ms B's failure to respond to 25 mg sildenafil makes the possibility of placebo effect less likely. It is also possible that her anorgasmia was a well-recognized side effect of antidepressant therapy (7) . This, however, also seems somewhat unlikely, because her anorgasmia predated antidepressant therapy by 8 years. Given the prevalence of female orgasmic disorder and the lack of good treatment, plausible new therapies should be considered. Further study of sildenafil for treatment of female orgasmic disorder is warranted.
